Results 91 to 100 of about 47,434 (363)

Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation

Clinical Cancer Research
Purpose: Liquid biopsy (LBx) for tumor profiling is increasingly used, but concerns remain regarding negative results. A lack of results may truly reflect tumor genomics, or it may be a false negative that would be clarified by tissue testing.
C. Rolfo, R. Madison, L. Pasquina, Derek W Brown, Yanmei Huang, Jason D Hughes, Ryon P. Graf, Geoffrey R. Oxnard, Hatim Husain   +8 more
semanticscholar   +1 more source

Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer

Nature Communications, 2021
Molecular stratification can improve the management of advanced cancers, but requires relevant tumor samples. Metastatic urothelial carcinoma (mUC) is poised to benefit given a recent expansion of treatment options and its high genomic heterogeneity.
G. Vandekerkhove, J. Lavoie, M. Annala, A. Murtha, N. Sundahl, S. Walz, T. Sano, S. Taavitsainen, E. Ritch, L. Fazli, A. Hurtado-coll, Gang-ping Wang, M. Nykter, P. Black, T. Todenhöfer, P. Ost, E. Gibb, K. Chi, B. Eigl, A. Wyatt   +19 more
semanticscholar   +1 more source

Tumor‐agnostic detection of circulating tumor DNA in patients with advanced pancreatic cancer using targeted DNA methylation sequencing and cell‐free DNA fragmentomics

Molecular Oncology, EarlyView.
We evaluated circulating tumor DNA (ctDNA) detection in advanced pancreatic cancer using DNA methylation, cell‐free DNA fragment lengths, and 5′ end motifs. Machine learning models were trained to estimate ctDNA levels from each feature and their combination.
Morten Lapin, Kjersti Tjensvoll, Karin Hestnes Edland, Satu Oltedal, Herish Garresori, Bjørnar Gilje, Saga Ekedal, Trygve Eftestøl, Jan Terje Kvaløy, Filip Janku, Oddmund Nordgård   +10 more
wiley   +1 more source

The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review [PDF]

, 2017
Background: The presence of circulating cell-free DNA from tumours in blood (ctDNA) is of major importance to those interested in early cancer detection, as well as to those wishing to monitor tumour progression or diagnose the presence of activating ...
A Castagnaro, A Melnikov, A Szpechcinski, AM Mazurek, AM Newman, Angela Cox, Anne Reiman, AR Thierry, B Gong, B Taback, Becky L. Whiteman, BH Kim, C Bettegowda, C Chiappetta, C Kneip, CF Eisenberger, CH Metz, CP Lange, D Hanahan, D Madhavan, Dawn Teare, DM Hyman, DM Kurtz, E Cassinotti, E Crowley, E Danese, E Heitzer, E Heitzer, E Kirkizlar, E Papadopoulou, E Zonta, ER Zaher, EY Rykova, F Andriani, F Diehl, F Perrone, F Salvianti, F Tian, G Huang, G Sharma, G Sozzi, G Weiss, Helen Buckley Woods, HS Hsu, Hugh Kikuchi, I Andolfo, I Ibanez de Caceres, I Skrypkina, IA Cree, IA Cree, Ian A. Cree, J Belic, J Ellinger, J Martinez-Galan, J Melson, J Tabernero, J Uchida, Jacqui Shaw, JD Warren, JM Yi, JY Wang, K Page, K Page, K Sikora, K Toth, K Warton, KL Aung, KL Spindler, L Benesova, L Chen, L De Mattos-Arruda, L Fernandez-Cuesta, L Sorber, L Uttley, Lesley Uttley, LS Kristensen, M Agostini, M Chimonidou, M Chimonidou, M de Martino, M Seefeld, M Shan, M Zane, MB Freidin, Michael Messenger, MJ Duffy, MO Hoque, NA Mohamed, NT Potter, Orla Sheils, P Jin, P Xia, PJ Johnson, PM Bossuyt, Q Zhang, QT Zhao, R Divella, R Dumache, R Grutzmann, R Mead, R Minciu, R Radpour, RA Zanetti-Dallenbach, RF Andersen, S Begum, S Couraud, S Hauser, S Kurihara, S McPhail, S Salvi, SC Pack, Sian Taylor Philips, SK Kadam, SR Payne, Susan Harnan, T deVos, T Powrozek, T Powrozek, TB Hao, TE Skvortsova, TR Church, U Ladabaum, V Kloten, V Swarup, X Lou, X Shao, XY Zhong, Y Zhang, YB Kuo, YJ Yang, YJ Zhang, YM Lo, YM Lo, YM Lo   +133 more
core   +3 more sources

Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial

Nature Network Boston
INTRIGUE was an open-label, phase 3 study in adult patients with advanced gastrointestinal stromal tumor who had disease progression on or intolerance to imatinib and who were randomized to once-daily ripretinib 150 mg or sunitinib 50 mg.
M. Heinrich, Robin L. Jones, Suzanne George, H. Gelderblom, P. Schöffski, M. von Mehren, J. Zalcberg, Yoon-Koo Kang, A. Razak, Jonathan C. Trent, S. Attia, A. Le Cesne, Brittany L. Siontis, D. Goldstein, K. Boye, César Sánchez, N. Steeghs, Piotr Rutkowski, M. Druta, C. Serrano, N. Somaiah, P. Chi, William Reichmann, K. Sprott, H. Achour, Matthew L Sherman, R. Ruiz-Soto, Jean-Yves Blay, S. Bauer   +28 more
semanticscholar   +1 more source

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

Molecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis   +11 more
wiley   +1 more source

Release of DNA and surfactant from gel particles: The receptor solution effect and the dehydration-hydration aspects [PDF]

, 2014
DNA and cetyltrimethylammonium bromide (CTAB) have been used to prepare gel particles for controlled release studies. This article reports on the release of DNA and CTAB in four different solutions: in sodium bromide, in strong acid, pH 2 and pH 9 ...
Mezei, Amália, Pons Pons, Ramon
core   +1 more source

ctDNA as a noninvasive monitoring tool in metastatic melanoma.

Journal of Clinical Oncology, 2019
9548 Background: The field of liquid biopsy provides a promising alternative to standard tissue biopsies. Previous work has shown that plasma circulating cell-free DNA (ctDNA) can reflect the heterogeneous spectrum of mutations in cancer including metastatic melanoma.
Varaljai, R., Wistuba-Hamprecht, K., Seremet, T., Diaz, JMS, Nsengimana, J., Sucker, A., Griewank, Klaus, Horn, Peter, von Neuhoff, N., Shannan, B., Chauvistre, H., Vogel, FCE, Horn, S., Becker, J. C., Newton-Bishop, J., Stang, Andreas, Neyns, B., Weide, B., Schadendorf, Dirk, Rösch, Alexander   +19 more
openaire   +2 more sources

Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)

Journal for ImmunoTherapy of Cancer, 2021
Background Currently available biomarkers are imperfect in their ability to predict responses to the multiple first-line treatment options available for patients with advanced non-small cell lung cancer (NSCLC).
B. Ricciuti, Greg Jones, Mariano Severgnini, J. Alessi, G. Recondo, M. Lawrence, T. Forshew, C. Lydon, M. Nishino, M. Cheng, M. Awad   +10 more
semanticscholar   +1 more source

Harnessing Photo‐Energy Conversion in Nanomaterials for Precision Theranostics

Advanced Materials, EarlyView.
Harnessing photo‐energy conversion in nanomaterials enables precision theranostics through light‐driven mechanisms such as photoluminescence, photothermal, photoelectric, photoacoustic, photo‐triggered surface‐enhanced Raman scattering (SERS), and photodynamic processes. This review explores six fundamental principles of photo‐energy conversion, recent
Jingyu Shi, Yadi Fan, Qin Zhang, Yingying Huang, Mo Yang   +4 more
wiley   +1 more source